Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jul-Sep;16(3):241-244.
doi: 10.14797/mdcj-16-3-241.

BRASH Syndrome with Hyperkalemia: An Under-Recognized Clinical Condition

Abdul Wahab Arif  1 , Muhammad Shahzeb Khan  1 , Abdallah Masri  1 , Benjamin Mba  1 , Muhammad Talha Ayub  2 , Rami Doukky  1   2
Affiliations
Case Reports

BRASH Syndrome with Hyperkalemia: An Under-Recognized Clinical Condition

Abdul Wahab Arif et al. Methodist Debakey Cardiovasc J. 2020 Jul-Sep.

Abstract

BRASH syndrome is characterized by bradycardia, renal failure, use of an atrioventricular nodal blocker (AVNB), shock, and hyperkalemia. These symptoms represent an ongoing vicious cycle in a patient with a low glomerular filtration rate taking an AVNB. Decreased clearance of the medication and hyperkalemia associated with renal failure synergize to cause bradycardia and hypoperfusion. This reaction causes renal function to worsen, thereby perpetuating the cycle of BRASH syndrome.

Keywords: BRASH syndrome; atrioventricular nodal blocker; bradycardia; hyperkalemia; renal failure; shock.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: The authors have completed and submitted the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement and none were reported.

Figures

Figure 1.
Figure 1.
Sinus rhythm with nonspecific T wave abnormalities.
Figure 2.
Figure 2.
Narrow-complex bradycardia.
Figure 3.
Figure 3.
The vicious cycle of BRASH syndrome. AVNB: atrioventricular nodal blocker
See this image and copyright information in PMC

References

    1. Diribe N, Le J. Trimethoprim/Sulfamethoxazole-Induced Bradycardia, Renal Failure, AV-Node Blockers, Shock and Hyperkalemia Syndrome. Clin Pract Cases Emerg Med. 2019 Aug;3(3):282–5. - PMC - PubMed
    1. Simmons T, Blazar E. Synergistic Bradycardia from Beta Blockers, Hyperkalemia, and Renal Failure. J Emerg Med. 2019 Aug;57(2):e41–e44. - PubMed
    1. Sohal S, Ramachandran A. Syndrome Of Bradycardia, Renal Failure, Atrioventricular Nodal Blockers, Shock, And Hyperkalemia (Brash Syndrome): A New Clinical Entity? Chest. 2019;156(4)
    1. Golchin A, Zhou M, Khan AH. Bradycardia, Renal Failure, AV-Nodal Blockers, Shock, and Hyperkalemia (BRASH) - A New Clinical Syndrome. Am J Respir Crit Care Med. 2018;197:A3467. (abstract)
    1. EMRA [Internet]. Tans CJ. BRASH Syndrome: Profound Bradycardia in the Setting of Mild Hyperkalemia. Irving, TX: EMRA; c2020. 2018 Oct 15 [cited 2020 Jul 5]. Available from: https://www.emra.org/globalassets/emra/be-involved/events–activities/cas....

Publication types

MeSH terms